260 related articles for article (PubMed ID: 21711431)
1. Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone.
Crawford ED; Moul JW; Rove KO; Pettaway CA; Lamerato LE; Hughes A
BJU Int; 2011 Dec; 108(11):1743-9. PubMed ID: 21711431
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen concentration in young men: new estimates and review of the literature.
Sutcliffe S; Pakpahan R; Sokoll LJ; Elliott DJ; Nevin RL; Cersovsky SB; Walsh PC; Platz EA
BJU Int; 2012 Dec; 110(11):1627-35. PubMed ID: 22502603
[TBL] [Abstract][Full Text] [Related]
3. Determining optimal prostate-specific antigen thresholds to identify an increased 4-year risk of prostate cancer development: an analysis within the Veterans Affairs Health Care System.
Sutton SS; Crawford ED; Moul JW; Hardin JW; Kruep E
World J Urol; 2016 Aug; 34(8):1107-13. PubMed ID: 26753559
[TBL] [Abstract][Full Text] [Related]
4. Benign prostatic hyperplasia: racial differences in treatment patterns and prostate cancer prevalence.
Pettaway CA; Lamerato LE; Eaddy MT; Edwards JK; Hogue SL; Crane MM
BJU Int; 2011 Oct; 108(8):1302-8. PubMed ID: 21371244
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen-based risk-adapted discontinuation of prostate cancer screening in elderly African American and Caucasian American men.
Tang P; Sun L; Uhlman MA; Robertson CN; Polascik TJ; Albala DM; Donatucci CF; Moul JW
Urology; 2010 Nov; 76(5):1058-62. PubMed ID: 20035982
[TBL] [Abstract][Full Text] [Related]
6. Serum prostate specific antigen levels in men with benign prostatic hyperplasia and cancer of prostate.
Amayo A; Obara W
East Afr Med J; 2004 Jan; 81(1):22-6. PubMed ID: 15080511
[TBL] [Abstract][Full Text] [Related]
7. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
8. Comparison of three assays for total serum prostate-specific antigen and percentage of free prostate-specific antigen in predicting prostate histology.
Roehrborn CG; Gregory A; McConnell JD; Sagalowsky AI; Wians FH
Urology; 1996 Dec; 48(6A Suppl):23-32. PubMed ID: 8973696
[TBL] [Abstract][Full Text] [Related]
9. Association of Prostate-Specific Antigen Velocity With Clinical Progression Among African American and Non-Hispanic White Men Treated for Low-Risk Prostate Cancer With Active Surveillance.
Nelson TJ; Javier-DesLoges J; Deka R; Courtney PT; Nalawade V; Mell L; Murphy J; Parsons JK; Rose BS
JAMA Netw Open; 2021 May; 4(5):e219452. PubMed ID: 33999164
[TBL] [Abstract][Full Text] [Related]
10. Earlier prostate-specific antigen testing in African American men--Clinical support for the recommendation.
Saltzman AF; Luo S; Scherrer JF; Carson KD; Grubb RL; Hudson MA
Urol Oncol; 2015 Jul; 33(7):330.e9-17. PubMed ID: 25937424
[TBL] [Abstract][Full Text] [Related]
11. Probability of an abnormal screening prostate-specific antigen result based on age, race, and prostate-specific antigen threshold.
Espaldon R; Kirby KA; Fung KZ; Hoffman RM; Powell AA; Freedland SJ; Walter LC
Urology; 2014 Mar; 83(3):599-605. PubMed ID: 24439009
[TBL] [Abstract][Full Text] [Related]
12. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Gould AL; Waldstreicher J
Urology; 1999 Mar; 53(3):581-9. PubMed ID: 10096388
[TBL] [Abstract][Full Text] [Related]
13. Interpreting results of prostate-specific antigen testing for early detection of prostate cancer.
Meigs JB; Barry MJ; Oesterling JE; Jacobsen SJ
J Gen Intern Med; 1996 Sep; 11(9):505-12. PubMed ID: 8905498
[TBL] [Abstract][Full Text] [Related]
14. Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men.
Moul JW; Sesterhenn IA; Connelly RR; Douglas T; Srivastava S; Mostofi FK; McLeod DG
JAMA; 1995 Oct; 274(16):1277-81. PubMed ID: 7563532
[TBL] [Abstract][Full Text] [Related]
15. Serum prostate-specific antigen discriminates weakly between men with benign prostatic hyperplasia and patients with organ-confined prostate cancer.
Sershon PD; Barry MJ; Oesterling JE
Eur Urol; 1994; 25(4):281-7. PubMed ID: 7519989
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen (PSA) and PSA density: racial differences in men without prostate cancer.
Henderson RJ; Eastham JA; Culkin DJ; Kattan MW; Whatley T; Mata J; Venable D; Sartor O
J Natl Cancer Inst; 1997 Jan; 89(2):134-8. PubMed ID: 8998182
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
18. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
Hudson MA; Luo S; Chrusciel T; Yan Y; Grubb RL; Carson K; Scherrer JF
Urol Oncol; 2014 Jan; 32(1):34.e9-18. PubMed ID: 23506962
[TBL] [Abstract][Full Text] [Related]
19. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
[TBL] [Abstract][Full Text] [Related]
20. Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng/mL total PSA.
Van Cangh PJ; De Nayer P; De Vischer L; Sauvage P; Tombal B; Lorge F; Wese FX; Opsomer R
Urology; 1996 Dec; 48(6A Suppl):67-70. PubMed ID: 8973703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
